Morgan Stanley Reiterates Buy Rating for Omada Health
Morgan Stanley reaffirms its buy rating for Omada Health, setting a price target of $30, a 61.29% upside from the current price.
Key Points
- Morgan Stanley reiterated its buy rating for Omada Health, Inc. on June 22, 2026, with a price target of $30.
- Morgan Stanley's $30 price target implies 61.29% upside from Omada Health, Inc.'s ($OMDA) current $18.60 share price.
- Shares of NasdaqGS:OMDA traded near $17.64 on Monday, with the company having a market cap of about $1.05 billion and a forward P/E ratio of 37.02.
- Several insiders, including Sachin Jain and Jonathan Root, bought shares on June 16, 2026, with no reported transaction value.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Morgan Stanley has reiterated its buy rating for Omada Health, Inc. (NasdaqGS:OMDA) on June 22, 2026. The firm set a price target of $30, indicating confidence in the company's future prospects. Omada Health's stock traded near $17.64 on Monday, reflecting the latest market sentiment.
Morgan Stanley vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
Omada Health, Inc. Stock Down 21.5%
Shares of Omada Health, Inc. were trading around $17.64 as of Monday. The company boasts a market capitalization of approximately $1.05 billion. Despite not being profitable, Omada Health has a forward P/E ratio of 37.02, suggesting growth expectations. The stock has ranged from a low of $10.28 to a high of $26.92 over the past year. Its 50-day moving average is $15.77, while the 200-day moving average is $17.25. Omada Health maintains a robust financial position with a current ratio of 3.92 and a quick ratio of 3.69.
$OMDA price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Recent Earnings
In its recent earnings report, Omada Health recorded revenue of $283.3 million, reflecting a growth rate of 42%. The company remains unprofitable, with an EPS of -$0.23 and a net margin of -2.22%. Its return on equity is -4.30%. Investors are looking forward to the next earnings announcement on August 6, 2026.
Insider Buying and Selling at Omada Health, Inc.
A group of insiders, including Sachin Jain, Jonathan Root, and others, each purchased 10,882 shares of Omada Health on June 16, 2026. These transactions were not planned under Rule 10b5-1 and did not specify a transaction value, indicating potential confidence in the company's future.
Analysts Set New Price Targets
Morgan Stanley reiterated its buy rating for Omada Health on June 22, 2026, with a price target of $30. Other analysts have also shown support, with Barclays, Citizens, and Evercore ISI Group maintaining buy ratings in recent months. The consensus among 12 analysts is a buy rating, with an average target price of $22.92, ranging from a low of $15 to a high of $30.
About Omada Health, Inc.
Omada Health, Inc. is a healthcare company based in South San Francisco, California. It provides virtual care programs focusing on cardiometabolic conditions such as prediabetes, diabetes, and hypertension, as well as physical therapy and weight management. Led by CEO Sean P. Duffy, the company offers its services to employers, health plans, and pharmacy benefits managers.
Bottom Line
Morgan Stanley's reiterated buy rating and $30 price target for Omada Health underscore the firm's confidence in the company's growth potential. With its focus on virtual healthcare solutions, Omada Health continues to attract attention from investors. However, as with all 13F filings and analyst ratings, these insights are backward-looking and do not necessarily reflect the current state of affairs.
Get Omada Health, Inc. alerts
New 13F filings, insider trades, and analyst moves on $OMDA, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.